The translation of new discoveries in the laboratory into better treatments for patients is a priority for the CRUK Cambridge Centre. Onco-innovation provides a collaboration point for our colleagues in the pharmaceutical industry as well as members from University departments in the physical sciences. It is the combination of disciplines that provide the greatest opportunity for innovation and novel approaches.

Jeffrey Cheah Biomedical Centre
The Milner Therapeutics Consortium

Cambridge is a hub for innovation and enterprise with a vibrant biotechnology and pharmaceutical industry, hosting over 440 life science and healthcare companies. The CRUK Cambridge Centre works closely with the Milner Therapeutics Consortium, which aims to transform pioneering science into therapies by driving research collaborations between academics and industry.

The Milner Therapeutics Institute will open its research labs in summer 2019, which will include the new AstraZeneca-CRUK Functional Genomics Centre, the Centre for Pathway Analysis and the Cambridge Centre for Proteomics. This will bring new opportunities for members of the Cancer Centre to collaborate with our industry partners.

Academic-industry collaborations

The Milner Therapeutics Consortium enables collaborative research by lowering the barriers of engagement between industry and academics. This Consortium consists of 3 academic institutes (Cambridge University, the Babraham Institute and the Sanger Institute) and 7 pharma companies (AstraZeneca, GSK, Shionogi, Astex, Janssen, Ferring and Pfizer). Using a pre-signed Consortium agreement, 19 projects have been established since 2015 with Cambridge researchers. Ten of these are focused on oncology with members of the Cancer Centre.

Milner Therapeutics Symposium 2019

The Milner Therapeutics Symposium 2019 was held on June 25th at the Cambridge Corn Exchange. This was the largest symposium to date with over 500 attendees and parallel tracks on oncology, CNS therapeutics, anti-microbial resistance & the microbiome, and cardiovascular & metabolism. With speakers across computational biology, chemistry and engineering, the event highlighted interdisciplinary advances in biomedical research. Research from the Cancer Centre was highlighted in five talks this year, in the plenary and oncology sessions.

How to engage with us

Our ethos is to enable collaboration across academia and industry. We have established a successful model to catalyse and sustain new partnerships in therapeutic research and would like to work with researchers, entrepreneurs and companies to determine how our model can be used to support you.